{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:50:02Z","timestamp":1778183402012,"version":"3.51.4"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["N01-AI-45250"],"award-info":[{"award-number":["N01-AI-45250"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201500002C"],"award-info":[{"award-number":["HHSN272201500002C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019R00027"],"award-info":[{"award-number":["75N93019R00027"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Previously, our group conducted the Herpevac Trial for Women, a randomized efficacy field trial of type 2 glycoprotein D (gD2) herpes simplex virus (HSV) vaccine adjuvanted with ASO4 in 8323 women. Study participants were selected to be seronegative for HSV-1 and HSV-2. We found that the vaccine was 82% protective against culture-positive HSV-1 genital disease but offered no significant protection against HSV-2 genital disease. Efficacy against HSV-1 was associated with higher levels of antibody to gD2 at enzyme-linked immunosorbent assay (ELISA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To better understand the results of the efficacy study, we measured postvaccination concentrations of neutralizing antibody (nAb) to either HSV-1 and HSV-2 from HSV-infected study participants and matched uninfected controls. Statistical modeling was used to determine whether these responses were correlated with protection against HSV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>nAbs to either HSV-1 or HSV-2 were correlated with ELISA binding antibodies to gD2. HSV-1 or HSV-2 nAb findings support the observation of protection by higher levels of antibody against HSV-1 infection, but the lack of protection against HSV-2 remains unexplained.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The protection against HSV-1 infection observed in the Herpevac Trial for Women was associated with nAbs directed against the virus, although the power to assess this was lower in the nAb study compared with the ELISA results owing to smaller sample size.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trials registration<\/jats:title>\n                  <jats:p>NCT00057330.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac067","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T12:10:30Z","timestamp":1645618230000},"page":"522-527","source":"Crossref","is-referenced-by-count":10,"title":["Neutralizing Antibody Kinetics and Immune Protection Against Herpes Simplex Virus 1 Genital Disease in Vaccinated Women"],"prefix":"10.1093","volume":"227","author":[{"given":"Robert B","family":"Belshe","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University School of Medicine , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara P","family":"Blevins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University School of Medicine , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinyi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University School of Medicine , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda E","family":"Nethington","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University School of Medicine , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbie","family":"Bellamy","sequence":"additional","affiliation":[{"name":"The EMMES Company , Rockville, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Bryant","sequence":"additional","affiliation":[{"name":"The EMMES Company , Rockville, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda A","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University School of Medicine , St Louis, Missouri , USA"},{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"2023021415120786700_CIT0001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine.","volume":"366","author":"Belshe","year":"2012","journal-title":"New Engl J Med"},{"key":"2023021415120786700_CIT0002","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cid\/cis891","article-title":"Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.","volume":"56","author":"Bernstein","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023021415120786700_CIT0003","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/infdis\/jit651","article-title":"Correlate of immune protection against HSV-1 genital disease in vaccinated women.","volume":"209","author":"Belshe","year":"2014","journal-title":"J Infect Dis"},{"key":"2023021415120786700_CIT0004","doi-asserted-by":"crossref","first-page":"e0144738","DOI":"10.1371\/journal.pone.0144738","article-title":"Higher throughput quantification of neutralizing antibody to herpes simplex viruses.","volume":"10","author":"Blevins","year":"2015","journal-title":"PLoS One"},{"key":"2023021415120786700_CIT0005","doi-asserted-by":"crossref","first-page":"e0214467","DOI":"10.1371\/journal.pone.0214467","article-title":"Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays.","volume":"14","author":"Blevins","year":"2019","journal-title":"PLoS One"},{"key":"2023021415120786700_CIT0006","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1016\/j.vaccine.2016.05.033","article-title":"Development of a high-throughput \u03b2-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples.","volume":"34","author":"Baccari","year":"2016","journal-title":"Vaccine"},{"key":"2023021415120786700_CIT0007","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/infdis\/jiu177","article-title":"Better neutralization of herpes simplex virus type (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.","volume":"210","author":"Awasthi","year":"2014","journal-title":"J Infect Dis"},{"key":"2023021415120786700_CIT0008","doi-asserted-by":"crossref","first-page":"e0176687","DOI":"10.1371\/journal.pone.0176687","article-title":"The Herpevac Trial for Women: sequence analysis of glycoproteins from viruses obtained from infected subjects.","volume":"12","author":"Minaya","year":"2017","journal-title":"PLoS One"},{"key":"2023021415120786700_CIT0009","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.02599-07","article-title":"Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.","volume":"82","author":"Hook","year":"2008","journal-title":"J Virol"},{"key":"2023021415120786700_CIT0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/scdb.1998.0242","article-title":"Viral interference with antibody and complement.","volume":"9","author":"Lubinski","year":"1998","journal-title":"Semin Cell Dev Biol"},{"key":"2023021415120786700_CIT0011","doi-asserted-by":"crossref","first-page":"e0212877","DOI":"10.1371\/journal.pone.0212877","article-title":"Molecular analyses and phylogeny of the herpes simplex virus 2 US9 and glycoproteins gE\/gI obtained from infected subjects during the Herpevac Trial for Women.","volume":"14","author":"Rowe","year":"2019","journal-title":"PLoS One"},{"key":"2023021415120786700_CIT0012","doi-asserted-by":"crossref","first-page":"eaax2454","DOI":"10.1126\/sciimmunol.aax2454","article-title":"HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses.","volume":"5","author":"Aschner","year":"2020","journal-title":"Sci Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac067\/43051817\/jiac067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/4\/522\/49178394\/jiac067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/4\/522\/49178394\/jiac067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T17:36:55Z","timestamp":1676396215000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/227\/4\/522\/6535411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2,24]]},"published-print":{"date-parts":[[2023,2,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac067","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,15]]},"published":{"date-parts":[[2022,2,24]]}}}